Sankoh A J, Huque M F, Dubey S D
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland 20857, USA.
Stat Med. 1997 Nov 30;16(22):2529-42. doi: 10.1002/(sici)1097-0258(19971130)16:22<2529::aid-sim692>3.0.co;2-j.
Confirmatory clinical trials often classify clinical response variables into primary and secondary endpoints. The presence of two or more primary endpoints in a clinical trial usually means that some adjustments of the observed p-values for multiplicity of tests may be required for the control of the type I error rate. In this paper, we discuss statistical concerns associated with some commonly used multiple endpoint adjustment procedures. We also present limited Monte Carlo simulation results to demonstrate the performance of selected p-value-based methods in protecting the type I error rate.
确证性临床试验通常将临床反应变量分为主要终点和次要终点。临床试验中存在两个或更多主要终点通常意味着可能需要对观察到的p值进行一些多重性检验调整,以控制I型错误率。在本文中,我们讨论了与一些常用的多终点调整程序相关的统计学问题。我们还给出了有限的蒙特卡罗模拟结果,以证明所选基于p值的方法在保护I型错误率方面的性能。